The History of Terrorism
Preview
Open in TheBrain
Links
MacroGenics
Children
2014 Janssen Biotech announced it would co-develop MacroGenics cancer drug candidate (MGD011) which targets both CD19 and CD3 proteins in treating B-cell malignant tumours. This could net MacroGenics up to $700 million.
Jumps
1979-Today Janssen Biotech (formerly Centocor Biotech, Inc.)